Colibrium

Colibrium Therapeutics is a biopharmaceutical company focused on the discovery and development of next-generation incretin-based therapies for obesity and metabolic diseases. The company was founded in 2024 by the leadership team behind Carmot Therapeutics, which was acquired by Roche for $2.7 billion. Colibrium leverages deep expertise in peptide and small molecule chemistry to create multi-receptor agonists targeting GLP-1, GIP, and glucagon receptors. Their goal is to improve upon existing weight-loss medications by enhancing potency, tolerability, and metabolic outcomes. The company is currently in the pre-clinical stage, advancing a pipeline of novel candidates designed to address the global metabolic health crisis.